Showing results (201-210 of 216) with videos related to

Sort By:
Pageof 22
ESMO Open|June 29, 2024
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerF Schettini, S Nucera, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative studyM Oliveira, C Falato, J M Cejalvo, et al.
ESMO Open|September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancerB Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer typesL Paré, T Pascual, E Seguí, et al.
ESMO Open|January 7, 2025
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancerL Angelats, L Paré, C Rubio-Perez, et al.
ESMO Open|October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialE Seguí, F Brasó-Maristany, T Pascual, et al.
Acta Otorrinolaringologica Espanola|June 12, 2026
Comprehensive Cancer Centre Accreditation: Experience and Achievements of a Head Neck Cancer UnitF X Avilés-Jurado, I Valduvieco, S Medrano-Martorell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Pageof 22